Exclusive Market Insight & Professional Analysis The most comprehensive resource center for the biotech industry

        Sign Up Today: Get Started, and get all the insight you want
  • Exclusive Posts

  • Industry Newsletters

  • Clinical Trials

  • Therapeutic Vaccines

  • Development-Stage Firm

  • Genomics

  • Gene Analysis

  • RNA Analysis

  • Possible Approvals

  • Stock Table

  • Possible Takeovers

  • Technology of the Week

  • Prohost Picks

  • And much more...

PROHOST NEWS AND COMMENTS

AGEN: IRRATIONAL REACTION AGAINST EXPECTED NEWS

  Thursday, March 20, 2014
 More...

PROSENSA: BACK INTO THE LIMELIGHT

  Tuesday, March 18, 2014

Prosensa Holding N.V. (RNA) might have good news that was made possible through insightful observation following past results that almost condemned the Dutch biopharmaceutical company’s compound drisapersen for the treatment of Duchenne Muscular Dystrophy (DMD).  More...

JAKAFI DEVELOPED BY INCYTE MET THE PRIMARY ENDPOINTS FOR POLYCYTHEMIA VERA

  Friday, March 07, 2014

Incyte (INCY) announced results from pivotal Phase 3 trial of Jakafi (ruxolitinib) in polycythemia vera patients who are resistant to or intolerant of hydroxyurea. The results met the primary endpoints; achieving phlebotomy independence and reducing spleen size by 35 percent or more compared to best available therapy.  More...

INCYTE: SHOWS ITS PATH TOWARDS GROWTH

  Wednesday, February 12, 2014

 More...

HALOZYME: FINANCING PEGPH20 IS WORTH RAISING MONEY

  Wednesday, February 05, 2014

Halozyme Therapeutics (HALO) stock has been a loser yesterday while other biotech firms have rebounded after dipping during the few days’ of an angry market. The reason for the stock decline was the announcement of pricing of Halozyme’s previously announced underwritten public offering of 7,692,307 shares of its common stock at a public offering price of $13.00 per share.  More...

INTERCEPT LIVER DRUG IS GAME CHANGER FOR THE BIOTECH INDUSTRY

  Friday, January 10, 2014

Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. Many people live with fatty livers, but in some of them only, the fat causes chronic inflammation of the liver - fibrosis – cirrhosis – liver failure and death. The disease is called Nonalcoholic steatohepatitis because its complications are similar to the liver disease that is caused by long-term, heavy alcohol drinking, but without being alcohol abusers. Currently there are no approved drugs to treat NASH.  More...

ARCA BIOPHARMA: A GENETICALLY TARGETED DRUG FOR ATRIAL FIBRILLATION IN HEART FAILURE PATIENTS

  Thursday, January 09, 2014

A Colorado-based biopharmaceutical company, ARCA Biopharma (ABIO) has a genetically-targeted drug, GencaroTM (bucindolol hydrochloride), for Atrial fibrillation (AF) in patients with heart failure (HF). The drug offers a personalized medicine approach for the treatment of AF in HF, treating only individuals with certain genetic characteristics. This approach enables the selection of individuals who would most probably respond to the drug through excluding the expected non-responders, thus reducing statistically failed trial outcome, in addition to decreasing clinical trial and healthcare costs.    More...

AMGEN INVESTIGATIONAL DRUG ROMOSOZUMAB IS PROMISING FOR POSTMENOPAUSAL OSTEOPOROSIS

  Thursday, January 02, 2014

Osteoporosis is caused by a progressive decrease in bone mass and density which increases the risk of fracture. The reduced, bone mineral density (BMD) impacts the bone architecture and alters the amount and variety of proteins in the bones.  More...

YES AMGEN IS THE KING

  Wednesday, December 18, 2013

When Amgen (AMGN) develops a drug, the wise King do whatever it takes to squeeze every drop of its therapeutic capability before submitting the new drug application (NDA) to the FDA for approval. The firm is rich in its science, scientists, pipeline of investigational products and its approved products. All the problems the firm encountered that analysts believed would erode its fortune, such as limiting the use of its growth factors did not impact the firm’s growth, but unveiled the character and culture that made the king deserve its throne.   More...

GILEAD SCIENCES: A UNIQUE STALLION

  Monday, December 09, 2013

Taking down Gilead (GILD) seems to be beyond the reach authors of tales intended to frighten investors into selling this outstanding stock. The attempts have been repetitive but short of success. Gilead is a stallion. Unlike stallions, the horses whose muscular superiority over other horses is genetically derived, Gilead’s power is acquired through a unique culture that embraces the power of intuition, self-confidence, common sense and courage. Using an optimal amount of faith, the firm turned intuition into inspiration and using courage and wisdom, the Stallion carried out inspired tasks fated unattainable by others.  More...

Join our FREE Email Updates, with the latest insight information about the biotech industry